Uptake of Autologous and Allogenic Tumor Cell Antigens by Dendritic Cells

Authors

  • A. Amanzadeh National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran
  • MA. Shokrgozar National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran
  • R. Mahdian Immune and Gene Therapy Lab, CCK, Karolinska Institute, Stock-holm, Sweden
Abstract:

Background: Dendritic cells (DCs) are professional antigen presenting cells (APCs), and there is considerable interest in their application as a cellular adjuvant for cancer immunotherapy.  Previous studies indirectly demonstrated that DCs were able to take up tumor lysate (crude soluble tumor antigens) and also cross-present tumor associated antigens (TAA) which elicits anti-tumor immune response.  Objective: To provide direct evidence that demonstrates the uptake of tumor lysate by DCs and to find out whether this capability is restricted to allogenic or autologous tumor lysate preparation.  Methods: DCs were generated from magnetic bead-isolated monocytes of B-CLL patients as well as healthy donors.  Proteins of tumor lysate were conjugated with FITC.  Their uptake by autologous as well as allogenic DCs was analyzed using FACS flowcytometry system.  Results: In both autologous and allogenic experiments, green fluorescence intensity (FL1) of immature DCs incubated with FITC-labeled tumor lysate was clearly higher than unpulsed counterparts, which were considered as background. Conclusion: Immature DCs are able to efficiently take up FITC-labeled tumor lysate of autologous as well as allogenic sources.  This finding confirms the results of previous studies, which have demonstrated that tumor lysate-pulsed DCs were able to elicit cytotoxic anti-tumor response and concluded that DCs could take up tumor lysate.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

uptake of autologous and allogenic tumor cell antigens by dendritic cells

background: dendritic cells (dcs) are professional antigen presenting cells (apcs), and there is considerable interest in their application as a cellular adjuvant for cancer immunotherapy.  previous studies indirectly demonstrated that dcs were able to take up tumor lysate (crude soluble tumor antigens) and also cross-present tumor associated antigens (taa) which elicits anti-tumor immune respo...

full text

Peroxynitrite-dependent killing of cancer cells and presentation of released tumor antigens by activated dendritic cells.

Dendritic cells (DCs), essential for the initiation and regulation of adaptive immune responses, have been used as anticancer vaccines. DCs may also directly trigger tumor cell death. In the current study, we have investigated the tumoricidal and immunostimulatory activities of mouse bone marrow-derived DCs. Our results indicate that these cells acquire killing capabilities toward tumor cells o...

full text

Acidosis improves uptake of antigens and MHC class I-restricted presentation by dendritic cells.

It is widely appreciated that inflammatory responses in peripheral tissues are usually associated to the development of acidic microenvironments. Despite this, there are few studies aimed to analyze the effect of extracellular pH on immune cell functions. We analyzed the impact of acidosis on the behavior of dendritic cells (DCs) derived from murine bone marrow. We found that extracellular acid...

full text

Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy.

Cross-presentation defines the unique capacity of an APC to present exogenous Ag via MHC class I molecules to CD8(+) T cells. DCs are specialized cross-presenting cells and as such have a critical role in antitumor immunity. DCs are routinely found within the tumor microenvironment, but their capacity for endogenous or therapeutically enhanced cross-presentation is not well characterized. In th...

full text

Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines.

The clinical impact of dendritic cells (DCs) in the treatment of human cancer depends on their unique role as the most potent antigen-presenting cells that are capable of priming an antitumor T-cell response. Here, we demonstrate that functional DCs can be generated from peripheral blood of patients with metastatic renal cell carcinoma (RCC) by culture of monocytes/macrophages (CD14+) in autolo...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 28  issue 2

pages  75- 80

publication date 2015-10-28

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023